Research progress in probiotics for the prevention and treament of Clostridium difficile-associated diarrhoea

XUE Chao-hui; ZHANG Lan-wei; WANG Shu-mei; LI Hong-bo

doi:10.13386/j.issn1002-0306.2013.22.090

Issue 22

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2013 > (22): 358-362. > DOI: 10.13386/j.issn1002-0306.2013.22.090

XUE Chao-hui, ZHANG Lan-wei, WANG Shu-mei, LI Hong-bo. Research progress in probiotics for the prevention and treament of Clostridium difficile-associated diarrhoea[J]. Science and Technology of Food Industry, 2013, (22): 358-362. DOI: 10.13386/j.issn1002-0306.2013.22.090

Citation:

PDF (631 KB)

Research progress in probiotics for the prevention and treament of Clostridium difficile-associated diarrhoea

School of Food Science and Engineering, Harbin Institute of Technology

More Information

Received Date: June 16, 2013

Graphical Abstract

Abstract

Abstract

With the increasing use of broad-spectrum antibiotics over the past two decades, the proportion and severity of Clostridium difficile-associated diarrhoea (CDAD) is increasing in health-care settings. Antibiotics remain the most important risk factor for CDAD, due to their limiting the ability of the gastrointestinal flora to inhibit C.difficile colonization. The antibiotics metronidazole and vancomycin have been showed to be effective in the treatment of CDAD. Despite appropriate antibiotic treatment, lots of patients with CDAD will experience disease recurrence. The use of probiotic bacteria to enhance the host flora, as either primary or secondary prophylaxis will be an effective. The currently accepted mechanism of inhibition of CDAD was as follows:inhibit of the growth of C.difficile, inhibit of the adhesion of C.difficile, stimulate the immune system. The diarrhea pathogenesis and epidemiological studies of C.difficile, as well as probiotics as the drug used in the treatment of CDAC, mechanism of probiotics inhibit the CDAC were described in this article.
- Clostridium difficile-associated diarrhoea,
- probiotics,
- S-layer proteins

FullText(HTML)

References (42)

References

[1]	ASLAM S, HAMILL R J, MUSHER D M.Treatment of Clostridium difficile-associated disease:old therapies and new strategies[J].The Lancet Infectious Diseases, 2005, 5 (9) :549-557.
[2]	CLOUD J, KELLY C P.Update on Clostridium difficile associated disease[J].Current Opinion in Gastroenterology, 2007, 23 (1) :4-9.
[3]	OWENS R C, DONSKEY C J, GAYNES R P, et al.Antimicrobial-associated risk factors for Clostridium difficile infection[J].Clinical Infectious Diseases, 2008, 46 (Supplement1) :S19-S31.
[4]	ASHA N, TOMPKINS D, WILCOX M.Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus[J].Journal of Clinical Microbiology, 2006, 44 (8) :2785-2791.
[5]	KLEVENS R M, EDWARDS J R, RICHARDS C L, et al.Estimating health care-associated infections and deaths in US hospitals, 2002[J].Public Health Reports, 2007, 122 (2) :160.
[6]	HIDRON A I, EDWARDS J R, PATEL J, et al.Antimicrobial resistant pathogens associated with healthcare associated infections:annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007[J].Infection Control and Hospital Epidemiology, 2008, 29 (11) :996-1011.
[7]	ARCHIBALD L K, BANERJEE S N, JARVIS W R.Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001[J].Journal of Infectious Diseases, 2004, 189 (9) :1585-1589.
[8]	REDELINGS M D, SORVILLO F, MASCOLA L.Increase in Clostridium difficile-related mortality rates, United States, 1999-2004[J].Emerging Infectious Diseases, 2007, 13 (9) :1417.
[9]	VOTH D E, BALLARD J D.Clostridium difficile toxins:mechanism of action and role in disease[J].Clinical Microbiology Reviews, 2005, 18 (2) :247-263.
[10]	LOWY I, MOLRINE D C, LEAV B A, et al.Treatment with monoclonal antibodies against Clostridium difficile toxins[J].New England Journal of Medicine, 2010, 362 (3) :197-205.
[11]	MUSHER D M, ASLAM S, LOGAN N, et al.Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole[J].Clinical Infectious Diseases, 2005, 40 (11) :1586-1590.
[12]	GERDING D N, MUTO C A, OWENS R C.Treatment of Clostridium difficile infection[J].Clinical Infectious Diseases, 2008, 46 (Supplement 1) :S32-S42.
[13]	MUTO C A.Health Care-Associated Clostridium difficile Infection[J].Gantz’s Manual of Clinical Problems in Infectious Disease, 2012, 285 (32) :246-252.
[14]	JOHNSON S, GERDING D N, LOUIE T J, et al.Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium difficile-Associated Diarrhea[J].Antimicrobial Agents and Chemotherapy, 2012, 56 (8) :4043-4045.
[15]	KELLY C P, LAMONT J T, CALDERWOOD S B.Treatment of Clostridium difficile infection in adults[J].UpToDate Weltham/MA, 2012, 46 (1) :32-42.
[16]	S ES L M, BROCK I, PERSSON S, et al.Clinical features of Clostridium difficile infection and molecular characterization of the isolated strains in a cohort of Danish hospitalized patients[J].European Journal of Clinical Microbiology&Infectious Diseases, 2012, 31 (2) :185-192.
[17]	LESSA F C.Community-Associated Clostridium difficile Infection:How real is it?[J].Anaerobe, 2013, 1 (6) :1-3.
[18]	OKA K, OSAKI T, HANAWA T, et al.Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases[J].Journal of Clinical Microbiology, 2012, 50 (3) :915-921.
[19]	ARMSTRONG G D, PILLAI D R, LOUIE T J, et al.A potential new tool for managing Clostridium difficile infection[J].Journal of Infectious Diseases, 2013, DOI: 10.1093/infdis/jit068.
[20]	GOLDENBERG J Z, MA S S, SAXTON J D, et al.Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children[J].Status and Date:New, published in, 2013, DOI: 10.1002/14651858.
[21]	PATTANI R, PALDA V A, HWANG S W, et al.Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients:systematic review and meta-analysis[J].Open Medicine, 2013, 7 (2) :56-67.
[22]	POZZONI P, RIVA A, BELLATORRE A G, et al.Saccharomyces boulardii for the prevention of antibioticassociated diarrhea in adult hospitalized patients:a singlecenter, randomized, double-blind, placebo-controlled trial[J].The American Journal of Gastroenterology, 2012, 107 (6) :922-931.
[23]	HEMPEL S, NEWBERRY S J, MAHER A R, et al.Probiotics for the prevention and treatment of antibioticassociated diarrhea a systematic review and meta-analysis[J].JAMA:the journal of the American Medical Association, 2012, 307 (18) :1959-1969.
[24]	BIENENSTOCK J, KLAENHAMMER T R, WALKER W A, et al.New insights into probiotic mechanisms:A harvest from functional and metagenomic studies[J].Gut Microbes, 2013, 4 (2) :1.
[25]	SCULLY P, MACSHARRY J, O’MAHONY D, et al.Bifidobacterium Infantis Suppression of Peyer’s Patch MIP-1αand MIP-1βSecretion During Salmonella Infection Correlates with Increased Local CD4+CD25+T Cell Numbers[J].Cellular Mmmunology, 2013, 281:134-141.
[26]	KAUR S, VAISHNAVI C, KOCHHAR R, et al.Effect of biotherapeutics on antitoxin IgG in experimentally induced Clostridium difficile infection[J].Indian Journal of Medical Microbiology, 2012, 30 (4) :431.
[27]	KELESIDIS T, POTHOULAKIS C.Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders[J].Therapeutic Advances in Gastroenterology, 2012, 5 (2) :111-125.
[28]	HU J-L, NIE S-P, MIN F-F, et al.Polysaccharide from Seeds of Plantago asiatica L.Increases Short-Chain Fatty Acid Production and Fecal Moisture along with Lowering pH in Mouse Colon[J].Journal of Agricultural and Food Chemistry, 2012, 60 (46) :11525-11532.
[29]	HAMER H M, DE PRETER V, WINDEY K, et al.Functional analysis of colonic bacterial metabolism:relevant to health?[J].American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012, 302 (1) :G1-G9.
[30]	DU TOIT E, VESTERLUND S, GUEIMONDE M, et al.Assessment of the effect of stress-tolerance acquisition on some basic characteristics of specific probiotics[J].International Journal of Food Microbiology, 2013, 165:51-55.
[31]	SALAZAR N, RUAS-MADIEDO P, PRIETO A, et al.Characterization of exopolysaccharides produced by Bifidobacterium longum NB667 and Its cholate-resistant derivative strain IPLA B667dCo[J].Journal of Agricultural and Food Chemistry, 2012, 60 (4) :1028-1035.
[32]	PATURI G, BENTLEY-HEWITT K L, BUTTS C A, et al.Dietary combination of potato resistant starch and red meat up regulates genes involved in colonic barrier function of rats[J].International Journal of Food Science&Technology, 2013, doi: 10.1111/ijfs.12208.
[33]	DHARMANI P, DE SIMONE C, CHADEE K.The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor[J].Plos One, 2013, 8 (3) :e58671.
[34]	XUE C, ZHANG L, LI H, et al.Functionality of the S-layer proteins from Lactobacillus in the competitive against enteropathogens infection[J].European Food Research and Technology, 2013, 236 (2) :249-255.
[35]	CHEN X, XU J, SHUAI J, et al.The S-layer proteins of Lactobacillus crispatus strain ZJ001 is responsible for competitive exclusion against Escherichia coli O157∶H7 and Salmonella typhimurium[J].International Journal of Food Microbiology, 2007, 115 (3) :307-312.
[36]	KANKAINEN M, PAULIN L, TYNKKYNEN S, et al.Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein[J].Proceedings of the National Academy of Sciences, 2009, 106 (40) :17193-17198.
[37]	GROSS G, SNEL J, BOEKHORST J T, et al.Biodiversity of mannose-specific adhesion in Lactobacillus plantarum revisited:strain-specific domain composition of the mannose-adhesin[J].Beneficial Microbes, 2010 (1) :61-6.
[38]	ROOS S, JONSSON H.A high-molecular-mass cell-surface protein from Lactobacillus reuteri 1063 adheres to mucus components[J].Microbiology, 2002, 148 (2) :433-442.
[39]	BUCK B L, ALTERMANN E, SVINGERUD T, et al.Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM[J].Applied and Environmental Microbiology, 2005, 71 (12) :8344-8351.
[40]	TEJERO-SARI ENA S, BARLOW J, COSTABILE A, et al.In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens:Evidence for the effects of organic acids[J].Anaerobe, 2012, 18:530-538.
[41]	NEAL-MCKINNEY J M, LU X, DUONG T, et al.Production of organic acids by probiotic lactobacilli can be used to reduce pathogen load in poultry[J].PloS One, 2012, 7 (9) :e43928.
[42]	GOURBEYRE P, DENERY S, BODINIER M.Probiotics, prebiotics, and synbiotics:impact on the gut immune system and allergic reactions[J].Journal of Leukocyte Biology, 2011, 89 (5) :685-695.

Supplements (0)

Get Citation

PDF

XML

Article Metrics

Article views (152) PDF downloads (354)

Science and Technology of Food Industry

Research progress in probiotics for the prevention and treament of Clostridium difficile-associated diarrhoea

Abstract

References

Catalog

Article Metrics

Export File

Citation

Format

Content